Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Trial of Dovitinib in Von Hippel-Lindau Syndrome
NCT01266070Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2012
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in von Hippel-Lindau syndrome (VHL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Most Frequent & Most Serious Adverse Events at 6 months. Started Nov 2012; status: terminated.
02
Drugs
dovitinib
03
Conditions
von Hippel-Lindau syndrome (VHL)
Beyond the preview
Go deeper on NCT01266070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266070.